#Checkmate 9la clinical study plus

These data will be featured in an oral presentation (Abstract #9000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2021, from 1:00 to 4:00 p.m.

#Checkmate 9la clinical study plus

The safety profile of Opdivo plus Yervoy with two cycles of chemotherapy reflected the established profiles of the immunotherapy and chemotherapy components in first-line NSCLC. 11.0 months with chemotherapy alone (Hazard Ratio 0.72 95% Confidence Interval : 0.61 to 0.86). With additional follow-up, median overall survival (OS), the trial’s primary endpoint, was 15.8 months with the dual immunotherapy combination vs. In the Phase 3 CheckMate -9LA trial, 38% of patients who received Opdivo plus Yervoy with two cycles of chemotherapy were alive at two years, compared to 26% of those who received chemotherapy alone.

PRINCETON, N.J.-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy showed a durable survival benefit compared to four cycles of chemotherapy alone after two years of follow-up in previously untreated patients with advanced non-small cell lung cancer (NSCLC). chemotherapy at two yearsĭual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histologyĭata to be featured in an oral presentation during the 2021 American Society of Clinical Oncology Annual Meeting Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs.